Revance Therapeutics (NASDAQ:RVNC – Get Free Report) released its earnings results on Tuesday. The biopharmaceutical company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.08), Briefing.com reports. Revance Therapeutics had a negative net margin of 224.65% and a negative return on equity of 1,091.00%. The company had revenue […]
- Q2 total revenue of $58.1 million, a YoY increase of 104.9%.- Q2 RHA® Collection revenue of $31.8 million, a YoY increase of 24.7%.- Q2 DAXXIFY® revenue of $22.6 million, a QoQ increase of 47.1%.- Bolstered financial position with $100 million net proceeds from ATM program and $50 million in notes available to be.
Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Free Report) shares traded down 10.1% during mid-day trading on Wednesday following a dissappointing earnings announcement. The company traded as low as $19.73 and last traded at $19.76. 1,460,632 shares were traded during mid-day trading, an increase of 3% from the average session volume of 1,423,772 shares. The stock […]
- Q2 total revenue of $58.1 million, a YoY increase of 104.9%.
- Q2 RHA® Collection revenue of $31.8 million, a YoY increase of 24.7%.
- Q2 DAXXIFY® revenue of $22.6 million, a QoQ increase of.
Revance Reports Second Quarter 2023 Financial Results, Provides Corporate Update wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.